Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
GENIUS Act Becomes First US Crypto Law After House Passage

GENIUS Act Becomes First US Crypto Law After House Passage

BeInCryptoBeInCrypto2025/07/17 11:41
By:Mohammad Shahid

The GENIUS Act passes the House, becoming the first US crypto law. It sets strict rules for stablecoin issuers and takes effect in 2026.

The US House has passed the GENIUS Act, officially sending it to President Trump, who is expected to sign it immediately. The bill received strong bipartisan support, with 306 votes in favor.

This makes the GENIUS Act the first federal crypto law in US history. It sets national standards for stablecoin issuance and oversight.

GENIUS Act Stablecoin Regulation Finally Passes

The GENIUS bill requires stablecoin issuers to hold 100% reserves, undergo regular audits, and register with federal or state regulators. It also bans unbacked algorithmic stablecoins.

Importantly, it introduces a dual-licensing structure—giving both federal and state authorities power to approve and supervise issuers.

Lawmakers passed the bill with strong bipartisan support. The Senate approved it earlier this month, making today’s House vote the final hurdle.

GENIUS Act Becomes First US Crypto Law After House Passage image 0US House Passes GENIUS Act Stablecoin Bill

President Trump’s administration helped broker the deal during this week’s political standoff. The legislation passed shortly after the CLARITY Act advanced through the House.

With Trump’s signature expected today, the law will take effect in 2026. Agencies like the Fed and OCC will now draft implementation rules.

For the crypto sector, this marks a turning point. US-regulated stablecoins now have a legal foundation to grow—with guardrails for safety and transparency.

However, critics warn the law could stifle smaller issuers and entrench big players like Circle and PayPal. Privacy advocates also raise concerns about surveillance risks.

Even so, the GENIUS Act now forms the regulatory bedrock for US dollar-backed stablecoins—an essential piece for crypto’s broader adoption.

What’s Next:

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales